Generic drug of the therapeutic class: Cardiology and angiology
active ingredients: Adenosine
laboratory: Sanofi-Aventis France
Injection solution for IV infusion
Box of 6 bottles of 10 ml
Intravenous adenoscan is a coronary vasodilator intended for use in myocardial perfusion scintigraphy when stress testing is impossible to perform or inappropriate.
Dosage ADENOSCAN 30 mg / 10 mL Solution for IV infusion Pack of 6 vials of 10 ml
Adenoscan is intended for hospital use where the means of cardiac supervision and cardiopulmonary resuscitation are immediately available if necessary.
It must be administered as for a stress test, under cardiological supervision by having the means of cardiopulmonary resuscitation.
During the administration of Adenoscan, continuous monitoring of the electrocardiogram is necessary because of the risk of occurrence of life-threatening arrhythmias. Heart rate and blood pressure should be checked every minute.
1. Adenoscan must be administered undiluted as a continuous peripheral intravenous infusion at a dosage of 140 μg / kg / min for 6 minutes using an infusion pump. It is recommended that Adenoscan and radiopharmaceutical be administered at different injection sites to avoid injecting adenosine.
2. The radiopharmaceutical is injected after 3 minutes of Adenoscan infusion while peak coronary blood flow occurs. Optimal vasodilatation occurs around the 6th minute of Adenoscan infusion.
3. In order to avoid a possible adenosine embol, the arterial pressure should be measured on the opposite arm to that receiving the Adenoscan infusion.
The table below specifies the infusion rate adjustment recommendations for undiluted Adenoscan, based on body weight (total dose 0.84 mg / kg).
Patient weight (kg)
Infusion rate (mL / min)
Tolerance and efficacy of adenosine in children aged 0 to 18 years have not been established. Currently available data are described under Pharmacodynamic properties, but no dosage recommendation can be made.
The elderly :
See dosage recommendations in adults.
Adenoscan is contraindicated in patients with the following conditions:
Hypersensitivity to the active substance or to any of the excipients,
· Second or third degree atrioventricular block, sinoatrial dysfunction (atrial disease), except for patients with pacemakers,
· Long QT syndrome,
· Severe hypotension,
· Unstable angina not stabilized by drug treatment,
· Decompensated heart failure,
· Chronic obstructive bronchopneumopathies with clinical bronchospasm (eg bronchial asthma),
· Combination with dipyridamole (see Drug Interactions).
Adenoscan side effects
The effects related to the pharmacological activity of adenosine are frequent but generally limited and of short duration. In the event of a serious adverse reaction, it may be necessary to stop the infusion.
Methylxanthines, such as aminophylline IV, or theophylline, have been used to treat persistent side effects (50-125 mg slow intravenous injection).
Adverse reactions are classified by organ / class system and frequency: very common (> 1/10), common (≥1 / 100, <1/10), infrequent (≥1 / 1000, <1/100), rare (≥1 / 10000, <1/1000), very rare (<1/10000), unknown (when the frequency can not be estimated from the available data).
· Common: Hypotension, sometimes severe (see Warnings and Precautions), ST-segment depression, sustained or unsupported ventricular tachycardia, atrioventricular block (see Warnings and Precautions for Use) caution and precautions for use). The infusion should be discontinued in case of prolonged atrioventricular block of the second or third degree. If first-degree atrioventricular block occurs, patients should be closely monitored because, in a quarter of cases, the block will progress to a higher degree.
· Uncommon: sometimes severe bradycardia (see Warnings and Precautions for Use)
· Unknown frequency: asystole / cardiac arrest (sometimes fatal, especially in patients with underlying ischemic disease / cardiac disorders, see Warnings and Precautions), sinus tachycardia, atrial fibrillation, ventricular fibrillation.
Nervous system disorders
· Very common: headache
· Common: dizziness, feeling of "empty head", paresthesia
· Rare: tremor, drowsiness
· Unknown frequency: unconsciousness / syncope, convulsions, especially in predisposed patients (see Warnings and Precautions)
· Rare: blurred vision
Affections of the ear and labyrinth
· Rare: tinnitus
Respiratory, thoracic and mediastinal disorders
· Very common: dyspnea (or need to breathe deeply)
· Rare: bronchospasm (see Warnings and precautions for use), nasal congestion
· Very rare: respiratory failure (see Warnings and Precautions for Use section Warnings and Precautions).
· Frequency unknown: apnea / respiratory arrest
Cases of fatal outcome of respiratory failure, bronchospasm and apnea / respiratory arrest have been reported.
· Very common: abdominal discomfort
· Common: dryness of the mouth
· Uncommon: metallic taste
· Unknown frequency: nausea, vomiting
Renal and urinary disorders
· Rare: urgent urgency
· Very common: facial flush
General disorders and administration site conditions
· Very common: chest pain or tightness, tight / oppressed chest sensation
· Frequent: discomfort in the throat, neck and jaw =)))))))
· Uncommon: Sweating, discomfort in the arms, legs or back, feeling weak / pain
· Very rare: reactions at the injection site
· Uncommon: nervousness
Disorders of reproductive organs and breast
· Rare: nipple discomfort